Nasdaq Biotech Index Gains Ground Lead By Adolor
The NBI rose more than 0.80% today as biotech finally awoke from a multi-day slump.
Shares of Adolor (ADLR) gaines more than 10% on the day after a Merril Lynch analyst upgraded the stock to a "buy" citing that its bowel dysfunction drug Entereq has a good chance of being approved. Shares of Adolor plummeted more than 40% a few weeks ago after 2 of its 3 clinical trials for Entereq failed to make their endpoints.
Is Adolor worth the risk? Well, the analyst explained the positive outlook based on the comparision between Entereq and a competing drug's trial design by Progenics Pharmaceuticals (PGNX). So why invest all in Adolor when you can dilute your investment into both companies?
__
The NBI rose more than 0.80% today as biotech finally awoke from a multi-day slump.
Shares of Adolor (ADLR) gaines more than 10% on the day after a Merril Lynch analyst upgraded the stock to a "buy" citing that its bowel dysfunction drug Entereq has a good chance of being approved. Shares of Adolor plummeted more than 40% a few weeks ago after 2 of its 3 clinical trials for Entereq failed to make their endpoints.
Is Adolor worth the risk? Well, the analyst explained the positive outlook based on the comparision between Entereq and a competing drug's trial design by Progenics Pharmaceuticals (PGNX). So why invest all in Adolor when you can dilute your investment into both companies?
__
posted by Nico at
7:44 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home